442 related articles for article (PubMed ID: 10598925)
21. Evaluation of cytokeratin 19 fragment (CYFRA 21-1) as a tumor marker in malignant pleural effusion.
Lai RS; Chen CC; Lee PC; Lu JY
Jpn J Clin Oncol; 1999 Sep; 29(9):421-4. PubMed ID: 10563194
[TBL] [Abstract][Full Text] [Related]
22. Assessment of serum CYFRA 21-1 in lung cancer.
Muraki M; Tohda Y; Iwanaga T; Uejima H; Nagasaka Y; Nakajima S
Cancer; 1996 Apr; 77(7):1274-7. PubMed ID: 8608502
[TBL] [Abstract][Full Text] [Related]
23. Cytokeratin 19 fragment CYFRA 21-1 compared with carcinoembryonic antigen, squamous cell carcinoma antigen and neuron-specific enolase in lung cancer. Results of an international multicentre study.
Ebert W; Dienemann H; Fateh-Moghadam A; Scheulen M; Konietzko N; Schleich T; Bombardieri E
Eur J Clin Chem Clin Biochem; 1994 Mar; 32(3):189-99. PubMed ID: 7518259
[TBL] [Abstract][Full Text] [Related]
24. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer.
Ando S; Kimura H; Iwai N; Shima M; Ando M; Kuriyama T
Anticancer Res; 2001; 21(4B):3085-92. PubMed ID: 11712815
[TBL] [Abstract][Full Text] [Related]
25. Immunoassay of neuron-specific enolase (NSE) and serum fragments of cytokeratin 19 (CYFRA 21.1) as tumor markers in small cell lung cancer: clinical evaluation and biological hypothesis.
Giovanella L; Piantanida R; Ceriani L; Bandera M; Novario R; Bianchi L; Roncari G
Int J Biol Markers; 1997; 12(1):22-6. PubMed ID: 9176714
[TBL] [Abstract][Full Text] [Related]
26. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer.
Foa P; Fornier M; Miceli R; Seregni E; Santambrogio L; Nosotti M; Cataldo I; Sala M; Caldiera S; Bombardieri E
Anticancer Res; 1999; 19(4C):3613-8. PubMed ID: 10629660
[TBL] [Abstract][Full Text] [Related]
27. Clinical utility of haptoglobin in combination with CEA, NSE and CYFRA21-1 for diagnosis of lung cancer.
Wang B; He YJ; Tian YX; Yang RN; Zhu YR; Qiu H
Asian Pac J Cancer Prev; 2014; 15(22):9611-4. PubMed ID: 25520076
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic value of tumour markers in pleural effusions.
Volarić D; Flego V; Žauhar G; Bulat-Kardum L
Biochem Med (Zagreb); 2018 Feb; 28(1):010706. PubMed ID: 29472801
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic value of CEA and CYFRA 21-1 tumor markers in primary lung cancer.
Okamura K; Takayama K; Izumi M; Harada T; Furuyama K; Nakanishi Y
Lung Cancer; 2013 Apr; 80(1):45-9. PubMed ID: 23352032
[TBL] [Abstract][Full Text] [Related]
30. Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in monitoring first-line chemotherapy of small cell lung cancer.
Holdenrieder S; von Pawel J; Dankelmann E; Duell T; Faderl B; Markus A; Siakavara M; Wagner H; Feldmann K; Hoffmann H; Raith H; Nagel D; Stieber P
Clin Cancer Res; 2008 Dec; 14(23):7813-21. PubMed ID: 19047109
[TBL] [Abstract][Full Text] [Related]
31. Value of tumour and inflammatory markers in lung cancer.
Oremek GM; Sauer-Eppel H; Bruzdziak TH
Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794
[TBL] [Abstract][Full Text] [Related]
32. Thymidine kinase 1 combined with CEA, CYFRA21-1 and NSE improved its diagnostic value for lung cancer.
Jiang ZF; Wang M; Xu JL
Life Sci; 2018 Feb; 194():1-6. PubMed ID: 29247745
[TBL] [Abstract][Full Text] [Related]
33. Diagnostic utility of CYFRA 21-1, carcinoembryonic antigen, CA 125, neuron specific enolase, and squamous cell antigen level determinations in the serum and pleural fluid of patients with pleural effusions.
Ferrer J; Villarino MA; Encabo G; Felip E; Bermejo B; Vilà S; Orriols R
Cancer; 1999 Oct; 86(8):1488-95. PubMed ID: 10526277
[TBL] [Abstract][Full Text] [Related]
34. Serum carbohydrate sulfotransferase 7 in lung cancer and non-malignant pulmonary inflammations.
Debeljak Ž; Dundović S; Badovinac S; Mandić S; Samaržija M; Dmitrović B; Miloš M; Maričić L; Šerić V; Buljanović V
Clin Chem Lab Med; 2018 Jul; 56(8):1328-1335. PubMed ID: 29648993
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of Cyfra 21-1 as a marker for lung cancer.
Najemnik C; Mohn-Staudner A; Vetter H; Kokron O; Baumgartner G; Scheiner W; Zwick H; Koderhold G; Alth G; Dudczak R
Wien Klin Wochenschr; 1996; 108(15):467-72. PubMed ID: 8806188
[TBL] [Abstract][Full Text] [Related]
36. Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and tissue polypeptide specific antigen (TPS) as tumour markers in lung cancer.
Stieber P; Dienemann H; Hasholzner U; Müller C; Poley S; Hofmann K; Fateh-Moghadam A
Eur J Clin Chem Clin Biochem; 1993 Oct; 31(10):689-94. PubMed ID: 7507359
[TBL] [Abstract][Full Text] [Related]
37. CYFRA 21-1 enzyme-linked immunosorbent assay. Evaluation as a tumor marker in non-small cell lung cancer.
Lai RS; Hsu HK; Lu JY; Ger LP; Lai NS
Chest; 1996 Apr; 109(4):995-1000. PubMed ID: 8635383
[TBL] [Abstract][Full Text] [Related]
38. [Tumor markers used in diagnosis and monitoring of primary bronchopulmonary carcinoma].
Mahler B
Pneumologia; 2008; 57(3):175-7. PubMed ID: 18998332
[TBL] [Abstract][Full Text] [Related]
39. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients.
Schneider J; Peltri G; Bitterlich N; Neu K; Velcovsky HG; Morr H; Katz N; Eigenbrodt E
Anticancer Res; 2003; 23(2A):899-906. PubMed ID: 12820320
[TBL] [Abstract][Full Text] [Related]
40. Diagnostic value of CYFRA 21-1 tumor marker and CEA in pleural effusion due to mesothelioma.
Paganuzzi M; Onetto M; Marroni P; Filiberti R; Tassara E; Parodi S; Felletti R
Chest; 2001 Apr; 119(4):1138-42. PubMed ID: 11296181
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
